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The APOBEC3 restriction factors are a family of deoxycytidine deaminases that are able
to suppress replication of viruses with a single-stranded DNA intermediate by inducing
mutagenesis and functional inactivation of the virus. Of the seven human APOBEC3
enzymes, only APOBEC3-D, -F, -G, and -H appear relevant to restriction of HIV-1 in CD4+T
cells and will be the focus of this review. The restriction of HIV-1 occurs most potently
in the absence of HIV-1 Vif that induces polyubiquitination and degradation of APOBEC3
enzymes through the proteasome pathway. To restrict HIV-1, APOBEC3 enzymes must
be encapsidated into budding virions. Upon infection of the target cell during reverse
transcription of the HIV-1 RNA into (−)DNA, APOBEC3 enzymes deaminate cytosines
to form uracils in single-stranded (−)DNA regions. Upon replication of the (−)DNA to
(+)DNA, the HIV-1 reverse transcriptase incorporates adenines opposite to the uracils
thereby inducing C/G toT/A mutations that can functionally inactivate HIV-1. APOBEC3G is
the most studied APOBEC3 enzyme and it is known that Vif attempts to thwart APOBEC3
function not only by inducing its proteasomal degradation but also by several degradation-
independent mechanisms, such as inhibiting APOBEC3G virion encapsidation, mRNA
translation, and for those APOBEC3G molecules that still become virion encapsidated, Vif
can inhibit APOBEC3G mutagenic activity. Although most Vif variants can induce efﬁcient
degradation of APOBEC3-D, -F, and -G, there appears to be differential sensitivity to Vif-
mediated degradation for APOBEC3H. This review examines APOBEC3-mediated HIV
restriction mechanisms, how Vif acts as a substrate receptor for a Cullin5 ubiquitin
ligase complex to induce degradation of APOBEC3s, and the determinants and functional
consequences of the APOBEC3 and Vif interaction from a biological and biochemical
perspective.
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OVERVIEW
Retrotransposons and endogenous retroviruses have been
genomic parasites in organisms throughout evolution and have
contributed to both species evolution and disease (Hancks and
Kazazian, 2012). The APOBEC (Apolipoprotein B mRNA-editing
enzyme-catalytic polypeptide) family of enzymes present in their
earliest form in bony ﬁsh acted as a defense to retroelements (Mac-
Duff et al., 2009). Due to expansion of retroelements through
evolution, there was a corresponding expansion in the APOBEC
family (Jern and Cofﬁn, 2008; LaRue et al., 2008). The most
recent expansion in placental mammals formed the APOBEC-
like 3 (APOBEC3) family in response to ancient pathogenic
retroviruses (LaRue et al., 2008; Munk et al., 2012). Humans con-
tain seven APOBEC3 (A3) enzymes (A3A, A3B, A3C, A3D, A3F,
A3G, and A3H, Jarmuz et al., 2002; LaRue et al., 2009). The A3
enzymes act as host restriction factors to inhibit retroelement
replication through either RNA binding ability or activity as
single-stranded (ss) DNA cytosine deaminases that catalyze the
formation of promutagenic uracils (Esnault et al., 2005; Bogerd
et al., 2006; Chiu et al., 2006; Jonsson et al., 2006; Armitage
et al., 2008; OhAinle et al., 2008; Khatua et al., 2010; Dug-
gal et al., 2011; Koyama et al., 2013). Currently, A3 enzymes
are primarily studied for their ability to restrict the replica-
tion of retroviruses (such as HIV-1, Sheehy et al., 2002; Harris
et al., 2003; Mangeat et al., 2003; Zhang et al., 2003; Lidda-
ment et al., 2004; Wiegand et al., 2004; Zheng et al., 2004; Dang
et al., 2006,2008;OhAinle et al., 2008; Richardson et al., 2014) and
other viruses with an ssDNA intermediate (such as Hepatitis B
Virus, Kock and Blum, 2008; Lucifora et al., 2014). Restriction
of the replication of these present day viruses occurs primarily
through the deoxycytidine deamination activity of A3 enzymes
which results in hypermutated and inactivated viral genomes. The
gene duplications that resulted in the humanA3 repertoire formed
two general groups of deaminases with different Zinc (Z) coordi-
nating domains: A3A, A3C, and A3H are enzymes with a single
Z-domain and A3B, A3G, A3D, and A3F enzymes with two Z-
domains (LaRue et al., 2008, Figure 1). For A3 enzymes with two
Z-domains, only one domain is catalytically active, except for A3B,
which may have two catalytically active domains (Hache et al.,
2005; Navarro et al., 2005; Bogerd et al., 2007; Bonvin and Greeve,
2007, Figure 1).
For HIV-1 (referred to as HIV) to successfully infect humans,
it must overcome numerous physical and immunological barriers
(Harris et al., 2012; ShawandHunter,2012; Xu et al., 2013).Within
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FIGURE 1 | Zinc (Z) coordinating-type domains of humanA3 enzymes.
A3 enzymes coordinate zinc through the motif H-X-E-X23−28-P-C-X2−4-C.
The glutamate activates a water molecule to enable zinc-hydroxide-
mediated nucleophilic attack to complete the deamination reaction.
Deamination activity has been demonstrated for all A3 enzymes. For the
enzymes with two Z-type domains that restrict HIV in CD4+T cells (A3D,
A3F, and A3G), a legend depicts known biochemical functions of each
Z-type domain. A common feature of A3 enzymes with two Z-type domains
is the segregation of functions in the N-terminal domain (NTD) and
C-terminal domain (CTD). The NTD is responsible for encapsidation and the
CTD is responsible for deamination activity. Both domains can bind nucleic
acids. The binding site of Vif is in the NTD for A3G and in the CTD for A3D
and A3F. The determinants for enzyme processivity have only been studied
for A3G and A3F. A3G and A3F processivity is imparted by the NTD.
cells, HIV must overcome a network of restriction factors that are
able to block speciﬁc replication steps of the virus, including A3
enzymes (Harris et al., 2012; Rahm and Telenti, 2012). HIV can
overcome these restriction factors through mutations or encod-
ing accessory proteins that speciﬁcally block the restriction factor
function (Harris et al., 2012; Rahm and Telenti, 2012). HIV uses
the viral infectivity factor (Vif) to overcome A3 enzymes (Sheehy
et al., 2002; Conticello et al., 2003; Harris et al., 2003; Mangeat
et al., 2003;Mariani et al., 2003). TheVif protein of simian immun-
odeﬁciency virus (SIV), the non-human primate form of the
virus, has co-evolved with species-speciﬁc A3s for millions of
years (Compton and Emerman, 2013). The HIV-1 predecessor,
SIVcpz from chimpanzees underwent a key evolutionary event that
altered the 3′ region of the vif gene that was essential for antag-
onism of human A3 function, along with further evolutionary
changes in chimpanzees that adapted SIVcpz for improved infec-
tion of humans (Etienne et al., 2013). To antagonize A3 enzymes,
HIV Vif must maintain the ability to physically interact with rele-
vant A3s, host protein CBFβ for stability (Jager et al., 2012; Zhang
et al., 2012), and components of the host ubiquitin ligase assem-
bly (Yu et al., 2003, 2004; Kobayashi et al., 2005; Xiao et al., 2006).
Ultimately Vif thwarts A3s by inducing their polyubiquitination
and degradation through the proteasome (Figures 2A,B). It is
thought that by disrupting the Vif–host cell interactions through
novel pharmaceuticals, A3 enzymes can be used to suppress HIV.
However, the natural balance of A3 enzymes and HIV must be ﬁrst
understood since there is evidence that HIV can take advantage of
A3 enzymes to accelerate its quasispecies evolution (Simon et al.,
2005; Kim et al., 2010).
From cell culture studies, it appears that only A3A, A3D,
A3F, A3G, and A3H are relevant to HIV restriction (Berger et al.,
2011; Hultquist et al., 2011; Koning et al., 2011; Refsland et al.,
2012; Chaipan et al., 2013). It is not surprising that not all seven
A3 members restrict HIV replication since they likely evolved
to restrict different retroelement pathogens (LaRue et al., 2008).
There are two paradigms of how A3 enzymes can suppress HIV.
A3A present in HIV target myeloid cells can restrict replication of
incoming virions through low levels of deamination and possibil-
ity another mechanism that is not yet fully elucidated (Berger
et al., 2011; Koning et al., 2011). In CD4+ T cells, A3D, A3F,
A3G, and A3H restrict HIVvif by becoming virion encapsi-
dated in the HIV producer cell and traveling with the virion
to the next susceptible cell where they catalyze promutagenic
deaminations of cytosine to uracil in nascent single-stranded
HIV (−)DNA (Hultquist et al., 2011, Figure 2A). Although A3B
can also restrict HIV in this manner in 293T or HeLa cells,
it is unable to become virion packaged and restrict HIV in T
cell lines, has low expression in activated T cells, and is not
antagonized by Vif, suggesting that restriction by A3B is not
physiologically relevant (Doehle et al., 2005; Koning et al., 2009;
Refsland et al., 2010; Hultquist et al., 2011; Pak et al., 2011). This
review will focus on the restriction of HIV by virion encapsi-
dated A3D, A3F, A3G, and A3H and how Vif antagonizes their
function.
A3-MEDIATED RESTRICTION OF HIV
The A3D, A3F, A3G, and A3H molecules that escape Vif-mediated
inhibition can restrict HIV by entering the assembling virus par-
ticle by binding RNA (HIV genome or cellular RNA such as
7SL or Y) that also interacts with the nucleocapsid (NC) por-
tion of the Gag polyprotein (Alce and Popik, 2004; Cen et al.,
2004; Douaisi et al., 2004; Svarovskaia et al., 2004; Burnett and
Spearman, 2007; Khan et al., 2007; Bach et al., 2008; Bogerd and
Cullen, 2008; Strebel and Khan, 2008; Wang et al., 2008; Ooms
et al., 2010; Zhen et al., 2012, Figure 2A). After the virus enters
the next target cell A3 enzymes exert their anti-viral function
during the reverse transcription process (Suspene et al., 2004; Yu
et al., 2004; Zheng et al., 2004; Dang et al., 2006; OhAinle et al.,
2008, Figures 2A,C). Although A3D, A3F, A3G, and A3H are
localized to the cytoplasm they require encapsidation to restrict
HIV and are not able to access the (−)DNA of an incom-
ing virus (Hultquist et al., 2011, Figure 2A). This may be due
to the HIV capsid structure or that A3 enzymes can reside in
regions of RNA processing, e.g., stress granules or P-bodies,
where they may have a role in sequestering human retrotrans-
poson RNA to prevent transposition (Chiu et al., 2006; Kozak
et al., 2006; Stopak et al., 2007; Gallois-Montbrun et al., 2008).
Since A3 enzymes are ssDNA deaminases, deamination activity
is restricted to the (−)DNA strand (Yu et al., 2004, Figure 2C).
The cytosine (C)−→uracil (U) deaminations catalyzed on the
(−)DNA strand become guanine (G)−→adenine (A) mutations
when reverse transcriptase (RT) uses U as a template during
(+)DNA strand synthesis (Yu et al., 2004, Figure 2C). The result-
ing “hypermutation” of the provirus leads to inactivation of
HIV (Harris et al., 2003; Mangeat et al., 2003; Zhang et al., 2003,
Figure 2A). Although it is known that many proviral genomes
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FIGURE 2 | Continued
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FIGURE 2 | Continued
Overview of HIV restriction by A3 enzymes. (A) Sketch depicting
lifecycles of wild-type (WT) and Vif HIV (Vif). Each virion enters a cell that
expresses A3 enzymes. In the WT virus, Vif is expressed in the cell and
recruits host cell CBFβ for stability and CRL5 E3 ubiquitin ligase complex
composed of Elongin B/C (EloB/C), Cullin5 (Cul5) and Rbx2 (B). In this
complex, Vif acts as the substrate receptor to induce degradation of A3
enzymes. As a result, assembling virions do not encapsidate high levels of
A3 enzymes and upon infection of a target cell the HIV lifecycle continues.
The Vif HIV encapsidates A3 enzymes through an RNA and Gag
interaction. In the target cell the A3 enzymes within the capsid of HIV can
deaminate cytosines to uracils in nascent single-stranded (−)DNA during
reverse transcription (C). These uracils induce G→A transition mutations
upon synthesis of (+)DNA (C). The resulting hypermutated virus can be
integrated into the host genome but is functionally inactivated. A3 enzymes
in the target cell cannot enter the HIV capsid and are unable to restrict virus
replication unless encapsidated into budding virions. (B) Detailed sketch of
Vif-mediated polyubiquitination of A3G. Vif interacts with Elongin C (EloC),
which forms an obligate heterodimer with Elongin B (EloB), and Cul5. The
transcription cofactor CBFβ stabilizes Vif. Cul5 binds to Rbx2and
subsequently recruits an E2 ubiquitin conjugating enzyme. Vif is the
substrate receptor that recruits A3 enzymes. The 48K-linked ubiquitin chains
result in proteasomal degradation of the A3. (C) Sketch demonstrating the
limited vulnerability of single-stranded (−)DNA to A3-mediated deamination
that is imposed from the dynamics of reverse transcription. Reverse
transcriptase is abbreviated as RT. HIV contains two polypurine tracts (PPT)
that are used as primers for (+)DNA synthesis. In the ﬁgure, only one PPT is
depicted. (D,E) Sketches depicting the stoichiometry of major virion
components for a (D)WT and (E) Vif HIV virion. Figures correspond to
(D) and (E) in (A). (D) Low amounts of A3 may escape Vif-mediated
degradation and become virion encapsidated (approximately one to two
molecules of A3G/virion). (E) A Vif HIV cannot induce degradation of A3
enzymes and that results in the encapsidation of A3 enzymes through an
interaction with RNA and Gag. Approximately 3–11 molecules of A3G can
become virion encapsidated. (D,E) Stoichiometry values for virions were
obtained from Camaur andTrono (1996), Fouchier et al. (1996), Cofﬁn et al.
(1997), Xu et al. (2007), Nowarski et al. (2008).
undergo successful integration with these hypermutations (Rus-
sell et al., 2009a), some preintegration complexes containing U
may be degraded by host DNA repair mechanisms, although there
is no consensus regarding the extent to which this occurs in cells
(Kaiser andEmerman,2006;Yang et al., 2007). In cell culture, it has
been found that the mutated HIV proteins that may be produced
from these proviral genomes can act as a source of HIV antigens
due to their misfolding and processing through the proteasome,
which can facilitate immune recognition of HIV (Casartelli et al.,
2010).
Each ssDNA deaminase acts within a preferred di- or tri-
nucleotide substrate motif. For A3G, this is 5′CCC or 5′CC (Yu
et al., 2004, 3′-end C preferred for deamination). A3D, A3F, and
A3Hdeaminate 5′TTCor 5′TCmotifs andA3Dcan also deaminate
5′GC motifs in proviral DNA (Liddament et al., 2004; Dang et al.,
2006; Ooms et al., 2013a). Although the majority of A3 actions are
repressed by Vif in HIV-infected individuals (Figures 2A,B,D),
clinical studies have found that individuals with an inherent abil-
ity to express a high level of A3G mRNA are less likely to become
infected with HIV or progress from HIV to AIDS and that the
presence of hypermutated proviral genomes correlates with high
CD4+ T-cell counts (Jin et al., 2005; Pace et al., 2006; Biasin
et al., 2007; Land et al., 2008; Vazquez-Perez et al., 2009). Other
A3 enzymes have not been extensively examined in this regard
(Albin and Harris, 2010; Ooms et al., 2013a). However, there is
evidence of deaminations inHIVgenomes recovered from infected
individuals due to C/G−→T/A mutations in a sequence context
that indicates deaminations by A3 enzymes other than A3G do
occur (Pace et al., 2006; Land et al., 2008; Vazquez-Perez et al.,
2009; Ooms et al., 2013a). For example, a study found that in
HIV-infected individuals there is approximately an equal split
between mutations occurring in the 5′TC and 5′CC contexts on
(−)DNA (Ooms et al., 2013a). However, there is difﬁculty pars-
ing out the effect of A3F, A3D, and A3H based on their mutation
patterns since they all recognize the minimal dinucleotide 5′TC
and are more promiscuous than A3G in regard to trinucleotide
target site preference (Liddament et al., 2004; Dang et al., 2006;
Hultquist et al., 2011). Nonetheless, it has become clear that
despite some evidence that A3G has more mutagenic potential
than other A3 deaminases, it is not acting alone against HIV (Ref-
sland et al., 2012; Chaipan et al., 2013; Ooms et al., 2013a). The
HIV genomes mutated through A3 catalytic activity are also sub-
ject to the pressure of purifying selection. This selection pressure
results in mutated and inactivated genomes being highest in inte-
grated proviral DNA and lowest in circulating viral RNA (Russell
et al., 2009a). Furthermore, integrated proviruses that are inacti-
vated by stop codons in the gag gene may still be rescued by dual
infection of a cell by HIV quasispecies and complementation of
Gag function (Russell et al., 2009a). Recombination within virions
by RT template switching can result in“reactivation”of inactivated
viral genomes (Mulder et al., 2008; Russell et al., 2009a). As a result,
A3-mediated mutagenesis is effective, but the complete inactiva-
tion of HIV in an infected individual is potentially a long-term
process that is likely to require multiple rounds of exposure to
viruses.
A3G-MEDIATED RESTRICTION OF HIV
Deamination-dependent HIV restriction by A3G
Since A3G was the ﬁrst A3 enzyme discovered A3G has been the
most widely studied for how it enacts its role as a restriction fac-
tor (over 700 publications in PubMed). There are two key steps
that A3G must complete to be an efﬁcient restriction factor. First,
the enzyme must be available for binding RNA that will become
virion encapsidated through an interaction with the NC portion
of Gag (Alce and Popik, 2004; Cen et al., 2004; Douaisi et al., 2004;
Svarovskaia et al., 2004; Burnett and Spearman, 2007; Khan et al.,
2007; Bach et al., 2008; Bogerd andCullen, 2008; Strebel andKhan,
2008; Wang et al., 2008). Second, it must have a mechanism to
search the nascentHIV (−)DNA, that is available for a ﬁnite period
of time, for potential cytosines that it can deaminate (Chelico et al.,
2006; Nowarski et al., 2008; Ara et al., 2014, Figure 2C).
A3G exists in cells as a high molecular mass that is bound to
RNA and other proteins in stress granules and P-bodies (Chiu
et al., 2006; Kozak et al., 2006; Wichroski et al., 2006; Gallois-
Montbrun et al., 2008). However, only newly synthesized A3G
that has not associated with host RNAs in these cytoplasmic struc-
tures appears to bind the RNA that is also bound by HIV Gag
and therefore encapsidated into virions (Soros et al., 2007). A3G
requires oligomerization to bind these RNAs effectively in cells
and become virion encapsidated (Wang et al., 2007; Bulliard et al.,
2009; Huthoff et al., 2009), but in vitro oligomerization mutants
of A3G can bind many RNAs with less than a threefold difference
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from wild-type (WT) A3G (Chelico et al., 2010; Feng and Che-
lico, 2011). The RNA binding and oligomerization of A3G is
primarily mediated by the N-terminal domain (NTD) and the
NTD is solely responsible for virion encapsidation of A3G (Hache
et al., 2005; Navarro et al., 2005; Huthoff et al., 2009; Chelico
et al., 2010, Figure 1). The NTD residues 124YYFW127 on pre-
dicted loop 7 mediate the dimerization of A3G (Huthoff et al.,
2009; Chelico et al., 2010, Figure 3A). A3G is primarily a dimer
in solution and when A3G binds RNA or DNA it oligomerizes
into tetramers and higher order structures through C-terminal
domain (CTD) residues 313RIYDDQ318 on loop 7 (Chelico et al.,
2008, 2010; Shlyakhtenko et al., 2011, Figure 3B). It is essen-
tial for A3G to enter the inner capsid of the virion to restrict
HIV. Within the capsid A3G can associate with the ribonucle-
oprotein complex and access the (−)DNA as it is synthesized.
A3 enzymes that cannot encapsidate within the HIV capsid, e.g.,
A3A and A3C, are unable to restrict HIV replication in CD4+
T cells (Goila-Gaur et al., 2007; Hultquist et al., 2011). However,
accessing the ribonucleoprotein complex does not guarantee the
ability to restrict HIV. Since the (−)DNA is only available for
a ﬁnite period of time due to HIV containing two polypurine
tracts (PPT) that are used to prime (+)DNA synthesis (Suspene
et al., 2006; Hu et al., 2010), A3 enzymes require an efﬁcient
mechanism to search for cytosines (Figure 2C). Complicating
the search is that the (−)DNA contains pieces of annealed RNA
due to the endonuclease activity of the RT-associated RNaseH
(Figure 2C). A3G binds RNA/DNA hybrids less well than ssDNA
and encountering these obstacles on the substrate can induce
A3G to dissociate from DNA (Iwatani et al., 2006; Chelico et al.,
2008).
Unraveling the mechanism by which A3G locates and catalyzes
its deamination motif is of pivotal importance for understanding
the mechanistic basis of proviral hypermutation. The mechanism
with which an A3 enzyme scans non-target DNA in search of its
deamination motif is a determinant in its catalytic efﬁciency (Feng
and Chelico, 2011; Ara et al., 2014). DNA scanning is described by
the term processivity and is deﬁned as the ability of an enzyme
to catalyze multiple events in a single enzyme–DNA substrate
encounter. Enzymes that do not use an energy source for move-
ment on DNA use a mechanism termed facilitated diffusion to
efﬁciently search DNA (Berg et al., 1981; von Hippel and Berg,
1989). This is a mechanism where the enzymes, subject to Brown-
ianmotion,move randomly onDNA. SinceDNA-bindingproteins
are usually positively charged, the negative charge of the DNA
facilitates the enzyme movement through electrostatic interac-
tions (Berg et al., 1981; von Hippel and Berg, 1989). A3G is a
positively charged enzyme (charge of +6.5 at pH 7) and proces-
sively scans ssDNA by facilitated diffusion (Chelico et al., 2006;
Nowarski et al., 2008, Figure 4). This mode is distinct from an
enzyme that acts on DNA distributively, where only one catalytic
event occurs before the enzyme disengages from the substrate
(Chelico et al., 2009). Facilitated diffusion can involve a variety
of movements such as 1-dimensional (D) sliding (Figure 4B)
or 3-D movements such as hopping/jumping (Figure 4C) or
intersegmental transfer (Figure 4D, Halford and Marko, 2004).
Hopping and jumping describe smallmicrodissociations and reas-
sociations with the same DNA strand without diffusion into the
bulk solution (von Hippel and Berg, 1989, Figure 4C). Intersege-
mental transfer involves a two-step mechanism where an enzyme
with two DNA-binding sites binds a second site before releasing
the ﬁrst site (von Hippel and Berg, 1989, Figure 4D). Facili-
tated diffusion works best when both 1- and 3-D movements
are used to enable local scanning of a small segment of DNA
by sliding (<20 nt) and movement to distal regions to restart
the local scanning process (Halford and Marko, 2004; Feng and
Chelico, 2011). These distal movements do not cause the enzyme
to leave the DNA and enter into the bulk solution because the
charged surface of the DNA keeps the enzyme within the domain
of the DNA (von Hippel and Berg, 1989, Figure 4C). Using
different methods A3G has been found to scan ssDNA by 1-D
sliding motions and 3-D jumping motions (Chelico et al., 2006;
Senavirathne et al., 2012; Shlyakhtenko et al., 2012). However, one
study has found that A3G moves by 3-D intersegmental transfers
(Nowarski et al., 2008). The efﬁciency imparted by a 3-D move-
ment in the speciﬁc case of A3G during reverse transcription is
that it provides a means of overcoming the DNA/RNA hybrid bar-
rier (Nowarski et al., 2008; Feng and Chelico, 2011). Clusters of
A3G-induced deaminations indicative of processive sliding move-
ments have been found in integrated proviral genomes (Browne
et al., 2009) and A3G mutants unable to undergo a local search-
ing process by 1-D sliding, such as H186R and A3G with an
195NPM197 insertion have decreased mutagenesis during in vitro
reverse transcription or in HIV proviral genomes (Feng and Che-
lico, 2011; Ara et al., 2014). Furthermore, an A3G F126A/W127A
mutant that cannot jump has decreased mutagenesis during in
vitro reverse transcription (Feng and Chelico, 2011). These data
demonstrate that neither movement alone can enable high lev-
els of A3G-induced mutagenesis. Interestingly, the F126A/W127A
mutant is monomeric, suggesting that the oligomeric state of A3G
plays a role in efﬁcient restriction of HIV not only by facilitat-
ing virion encapsidation but also by facilitating the DNA scanning
process (Huthoff et al., 2009; Chelico et al., 2010; Feng andChelico,
2011). The processivity determinants of A3G reside on predicted
loop 7 and helix 6 of the non-catalytic NTD (Feng and Chelico,
2011; Ara et al., 2014, Figure 3A). Thus, despite a lack of cat-
alytic activity, theNTDcontributes toA3Gdeamination activity by
mediating the processive scanning mechanism (Feng and Chelico,
2011).
Deamination-independent HIV restriction by A3G
A3G primarily restricts HIV replication through its deamination
activity. However, there have been numerous reports of an abil-
ity of A3G to physically inhibit other processes of HIV such
as RT polymerization (Iwatani et al., 2007; Bishop et al., 2008;
Wang et al., 2012; Adolph et al., 2013; Belanger et al., 2013; Gillick
et al., 2013), NC strand annealing (Guo et al., 2006, 2007), and
proviral DNA integration (Luo et al., 2007; Belanger et al., 2013).
These processes do not occur in isolation from deamination, nor
do they restrict HIV better than deamination alone (Belanger
et al., 2013; Gillick et al., 2013). We will focus on inhibition of
RT polymerization since this is the most prevalent mechanism
studied.
Early studies of A3G-mediated restrictionof HIVproposed that
transiently overexpressed WT A3G and deamination null mutants
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FIGURE 3 | Structures of A3 enzymes. A3 enzymes have a basic
structure in each Z-type domain that is composed of a ﬁve-stranded
β-sheet core surrounded by six α-helices. Numerical assignments to
β-strands and α-helices are superimposed in (A). Zinc atoms are shown
as blue spheres. (A) Model of the N-terminal domain (NTD) of A3G.
Loop 7 (L7) of the A3G NTD is a central structure in its anti-HIV
function. Highlighted on L7 are the residues important for interaction
with Vif (red, 128DPD130), oligomerization/virion encapsidation (green and
cyan, 124YYFW127), and jumping component of A3G processivity (cyan,
126FW127). Helix 6 (h6) is adjacent to L7 and contributes to the sliding
component of A3G processivity, particularly 186H (cyan). The model of
the A3G NTD was obtained by using the automated SWISS-MODEL
program using the homologous A3G C-terminal domain structure (CTD,
PDB: 3IQS). (B) The A3G CTD (PDB: 2KEM) is the catalytic domain of
A3G. The A3G CTD has a discontinuous β2 strand forming a loop-like
bulge between the β2 and β2′ strands. A3G L7 residues 313RIYDDQ318
(green) mediate tetramerization and determine the preferred deamination
motif. (C) The model of the A3F NTD was obtained by using the
automated SWISS-MODEL program using the homologous A3C structure
(PDB: 3VM8). The end of h6 connects the NTD to the CTD and
contains an 190NPM192 motif. This NPM motif is found only in A3D
and A3F. (D) The A3F CTD (PDB: 4IOU) is the catalytic domain of A3F
and interacts with Vif. Residues that interact with Vif across Helix 2, 3,
4, and β-strand 4 are shown in red. Also shown on this structure is
the deamination motif speciﬁcity loop (L7) and the 190NPM192 motif.
The structure illustrates the kinked orientation introduced by the Pro in
the 190NPM192 motif, which blocks the sliding function of A3F. (E) The
model of the CTD of A3D was obtained by using the SWISS-MODEL
program using the homologous A3F structure (PDB: 4IOU). Residues
that interact with Vif across Helix 2, 3, 4, and β-strand 4 are shown in
red. The 320C residue on L7 that inﬂuences A3D activity is shown in
orange. (F) Model of A3H Hap II showing residues that interact with Vif
and cause haplotype instability. In A3H Hap II, 121D (red) on predicted
h4 mediates an interaction with Vif. In A3H Hap I the R105G mutation
induces protein instability (magenta). In A3H Hap III and IV, the deletion
of 15N induces protein instability (magenta). The model of the A3H Hap
II was obtained by using the automated SWISS-MODEL program using
the homologous APOBEC2 structure (PDB: 2NYT). Figures were made
using PyMOL (The PyMOL Molecular Graphics System, Version 1.5.05,
Shrödinger, LLC.).
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FIGURE 4 | Illustration of DNA scanning by facilitated diffusion.
(A) Sketch of DNA showing the negatively charged region of DNA
important for facilitated diffusion of A3 enzymes. (B–D) Enzyme in sketches
is shown as a dimer, although the oligomerization state may vary with
different A3 enzymes. (B) Sketch depicting a 1-dimensional DNA scanning
path by sliding. Dotted line indicates path of enzyme (orange). Sliding
enables an in depth search of local areas of a substrate. (C) Sketch
depicting a 3-dimensional DNA scanning path by jumping. Jumping enables
larger translocations on DNA substrates, but lacks a local search process.
The microdissociations of the enzyme from the DNA that occur when the
enzyme jumps does not leave the negatively charged domain of the DNA
so the enzyme has a higher likelihood of reassociating with the same DNA
substrate than diffusion into the bulk solution. (D) Sketch depicting a
3-dimensional DNA scanning path by intersegmental transfer.
Intersegmental transfer enables larger translocations on DNA substrates,
but lacks a local search process. An enzyme with two DNA-binding domains
binds two regions of DNA simultaneously before dissociating from one
region to move to another.
of A3G could inhibit HIV proviral DNA formation (Mangeat
et al., 2003; Newman et al., 2005). The initial mechanism pro-
posed was that A3G binds the HIV genomic RNA which impedes
RT (Iwatani et al., 2007). This has been conﬁrmed in multiple
reports using cellular and biochemical experiments (Adolph et al.,
2013; Belanger et al., 2013; Chaurasiya et al., 2014). However, the
physiological signiﬁcance of these processes is difﬁcult to recon-
cile since results from cell-based experiments using transiently
expressed A3G cannot be replicated when A3G is stably expressed,
suggesting that overexpression of A3G induced experimental arti-
facts due to excessive packaging of A3G in virions (Mbisa et al.,
2007; Miyagi et al., 2007; Schumacher et al., 2008; Browne et al.,
2009). Importantly, studies that used deamination null mutants
of A3G to show that deamination ability is required for restriction
of HIV (Mbisa et al., 2007; Miyagi et al., 2007; Schumacher et al.,
2008) should be considered in conjunction with data showing that
the A3G E259Q catalytically inactive mutant is not a true proxy
for A3G (Bishop et al., 2008; Adolph et al., 2013). A3G E259Q
binds RNA less well than A3G and this results in less inhibi-
tion of RT in vitro and in cells (Bishop et al., 2008; Adolph et al.,
2013).
Nonetheless, it is clear that the ability of A3G to inhibit RT is
highly dependent on A3G concentration and the primer/template
(Mbisa et al., 2007; Miyagi et al., 2007; Schumacher et al., 2008;
Browne et al., 2009; Adolph et al., 2013). The initiation of DNA
synthesis from an RNA primer on an RNA template is the
least efﬁcient type of polymerization activity of RT (Liu et al.,
2010). Accordingly, in vitro, low levels of A3G can best inhibit
RT-mediated primer initiation at this step by competing for sub-
strate (Iwatani et al., 2007; Adolph et al., 2013). In contrast, on a
DNA primer and DNA template, A3G could at most inhibit in
vitro RT-mediated initiation of synthesis by twofold under sin-
gle turnover conditions and could not block RT from binding the
primer/template, but merely lengthened the time RT required to
ﬁnd the free 3′OH (Adolph et al., 2013). These data are in agree-
ment with a computational study that suggests an A3G-mediated
deamination-independent mode of HIV restriction contributes
<1% of the restriction capability of A3G (Kobayashi et al., 2014).
Although studies have shown that a peptide of A3G can interact
with RT and inhibit RT-mediated DNA synthesis, it is unlikely
that this mechanism is a physiological way to inhibit reverse tran-
scription since in Vif virions, only 3–11 A3G molecules are
encapsidated whereas there are approximately 100 RT molecules
(Cofﬁn et al., 1997; Xu et al., 2007;Wang et al., 2012, Figure 2E). In
the presence of Vif, there is only an estimated one to two molecules
of A3G per virion (Nowarski et al., 2008, Figure 2D), empha-
sizing the importance of a deamination-dependent mechanism
over a deamination-independent mechanism. A single molecule
of A3G could inactivate an HIV provirus through cytosine deami-
nationwhereas the deamination-independentmechanism ismuch
more concentration dependent (Browne et al., 2009; Adolph et al.,
2013). Single-molecule studies have brought forth the model that
A3G oligomers can act as a road-block for HIV (Chaurasiya
et al., 2014). Notably, existence of a deamination-independent
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mode of HIV inhibition has been observed ex vivo in primary
cells (Gillick et al., 2013), but it requires further research as
to the signiﬁcance of this mode of inhibition during an HIV
infection.
A3F-MEDIATED RESTRICTION OF HIV
Deamination-dependent HIV restriction by A3F
Approximately 2 years after the discovery of A3G,A3F was discov-
ered to also exhibit restriction activity against HIV (Liddament
et al., 2004; Wiegand et al., 2004; Zheng et al., 2004). Sequenced
HIV proviral genomes were known to contain G/C−→A/T tran-
sition mutations in 5′CC and 5′TC contexts in the (−)DNA
(Pathak and Temin, 1990; Li et al., 1991; Vartanian et al., 1991,
2002; Fitzgibbon et al., 1993) and A3F was found to contribute to
transition mutations in the 5′TC context. Of these initial studies
demonstratingA3F activity active against HIV (Bishop et al., 2004;
Liddament et al., 2004; Wiegand et al., 2004; Zheng et al., 2004), all
except one (Zennou andBieniasz, 2006) found thatA3F restriction
activity was equivalent toA3G restriction activity. It has since been
shown that overexpression of A3 enzymes can result in excessive
packaging into HIV virions and result in artifacts of HIV restric-
tion (Miyagi et al., 2007; Xu et al., 2007; Schumacher et al., 2008).
Yet even after 10 years of studying A3F, multiple groups still ﬁnd
different activities of A3F against HIV that cannot be attributable
to overexpression, but perhaps different experimental systems and
techniques (Miyagi et al., 2010; Mulder et al., 2010; Hultquist et al.,
2011; Chaipan et al., 2013; Ara et al., 2014). However, A3F must
exert a restriction pressure on HIV since Vif maintains an inter-
action interface with A3F that is distinct from A3G in order to
induce A3F degradation (Russell et al., 2009b). As with A3G, for
A3F to effectively restrict HIV, it must be encapsidated with the
ribonucleoprotein complex within the capsid (Wang et al., 2008)
and effectively search for cytosines on the heterogeneous (−)DNA
substrate (Ara et al., 2014).
A3F encapsidates into HIV virions through an interaction with
RNA, but packages more efﬁciently than A3G into the core of
HIV particles (Zennou and Bieniasz, 2006; Wang et al., 2008;
Song et al., 2012). By resolving HIV capsids on a sucrose gra-
dient to observe whether A3F and A3G partition with the RNA
and enzymes or the p24 capsid protein, Song et al. (2012) found
that more A3F speciﬁcally associated with the ribonucleoprotein
complex, in comparison to A3G. A3F binds nucleic acids with
sevenfold higher afﬁnity than A3G (Ara et al., 2014), which may
enable it to package more speciﬁcally within the capsid (Song
et al., 2012). Furthermore, A3F has been shown to bind double-
stranded DNA with a higher afﬁnity than A3G and maintain an
association with the pre-integration complex of HIV as it enters
the nucleus through its high-afﬁnity nucleic acid binding (Mbisa
et al., 2010; Burdick et al., 2013). Despite the quantity of A3F
being at an equal or greater amount to A3G, A3F restricted HIV
approximately fourfold less than A3G in a single round of infec-
tion (Song et al., 2012). Although some reports show A3F can
be less effective than A3G in restricting HIV (Miyagi et al., 2010;
Mulder et al., 2010; Song et al., 2012; Chaipan et al., 2013; Ara
et al., 2014), it cannot be concluded that it does not suppress HIV
or impose selective pressure on HIV. Not only because of data
showing A3F can effectively restrict HIV in spreading infections
(Hultquist et al., 2011; Refsland et al., 2012), but also because an
HIV lab strain with tandem stop codons in Vif (from HIV NL4-
3) will revert back to expressing a functional Vif in the presence
of A3F (Albin et al., 2010a). This does not occur when A3G is
used in the same type of forced evolution experiments (Hache
et al., 2008, 2009). The HIV evolves to overcome A3G restriction,
but does so by acquiring a 5′UTR mutation to make HIV RNA
transcription more efﬁcient and altering the cell cycle through a
Vpr mutation (Hache et al., 2008, 2009). Together these mutations
result in more virus particles being produced. Presumably since
A3G has less speciﬁc packaging in the capsid than A3F, this strat-
egy titrates out the ribonucleoprotein-packaged A3G enabling the
HIV to escape high levels of mutagenesis. These data illustrate that
A3G and A3F exert a distinct selective pressure on HIV due to dis-
tinct biochemical properties and that A3 packaging into virions is
a necessary but insufﬁcient step to ensure efﬁcient HIV restriction
(Ara et al., 2014).
To further understand why A3F-mediated restriction of HIV
may be different than for A3G, Ara et al. (2014) undertook a
biochemical study of A3F in comparison to A3G to identify bio-
chemical differences between these enzymes that could account for
differences in restriction efﬁciency. They found that in contrast to
A3G, A3F used only 3-D jumping motions to scan ssDNA. This
made the DNA scanning mechanism inefﬁcient since A3F could
translocate between many ssDNA regions and overcome interven-
ingRNA/DNAhybrid regions, but lacked a local searchmechanism
to examine ssDNA regions for its 5′TC motif (Figure 4C). The
A3F sliding movement is blocked by a 190NPM192 motif in the
connection domain between the NTD and CTD (Figures 3C,D)
since mutagenesis of this motif to 190NGM192enabled A3F to
slide (Ara et al., 2014). The Bohn et al.’s (2013) A3F CTD struc-
ture includes the 190NPM192 sequence and shows that it is a
kinked region of the loop structure (Figure 3D). Since an A3F
190NGM192 mutant was able to slide, the data suggest that the
rigid 191P residue primarily blocks sliding. However, imparting
sliding movement to A3F through the 190NGM192 mutant did
not increase A3F HIV restriction efﬁciency because the jump-
ing movements of A3F differed from A3G and were dominant
over sliding which maintained an inefﬁcient search of ssDNA
(Ara et al., 2014). The differences in DNA scanning between
A3F and A3G were shown to be relevant to HIV restriction
since A3F was fourfold less effective in restriction of HIV than
A3G in a single-cycle infectivity assay (Ara et al., 2014). Of note,
A3F was also shown to have a 100-fold lower speciﬁc activ-
ity than A3G (Ara et al., 2014), but this was not thought to
contribute to differences in restriction efﬁciency since studies
with different A3G and A3F mutants showed that mutagenesis
efﬁciency correlated with the efﬁciency of the ssDNA scanning
mechanism, not the speciﬁc activity. This is likely because RT
polymerization and RNaseH activity limit the (−)DNA substrate
available (Feng et al., 2013). The study by Ara et al. (2014) is
in agreement with studies where A3F has not been as effec-
tive as A3G in restriction of HIV (Miyagi et al., 2010; Mulder
et al., 2010; Chaipan et al., 2013), although A3F was found to
be as restrictive to HIV replication as A3G in other reports
(Hultquist et al., 2011; Refsland et al., 2012). Despite A3F being
considered in some reports to be less efﬁcient than A3G as an
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HIV restriction factor when considered side by side, this is far
from the natural mechanism of these enzymes in which they act
in concert (Refsland et al., 2012; Ooms et al., 2013a) and fur-
ther studies examining how these enzymes work together are
needed.
It is of note that Zennou and Bieniasz (2006) noticed that
per mutation, A3F was less likely to inactivate HIV than A3G.
This was later found to be because the 5′CC motif of A3G over-
laps with the only Trp codon (5′TGG/ACC) and results in a stop
codon upon deamination of either cytosine in the motif (Yu et al.,
2004). In contrast, A3F-induced mutations largely result in mis-
sense mutations which may or may not inactivate the encoded
protein (Ara et al., 2014). The A3G 5′CC motif also overlaps
with Gly codons and in the HIV prot mutations at these Gly
results in more non-conservative mutations and gene inactiva-
tion than A3F-induced missense mutations that primarily cause
the conservative mutation of Glu to Gln (Ara et al., 2014). The
determinant for motif speciﬁcity is loop 7 in the CTD (Lan-
glois et al., 2005; Kohli et al., 2009; Carpenter et al., 2010; Rathore
et al., 2013, Figures 3B,D). This loop can be grafted into dif-
ferent A3 enzymes to change site speciﬁcity (Kohli et al., 2009).
However, the consequences of deamination mediated restriction
can be independent from inducing amino acid changes. A3F and
A3G may be able to block proviral integration through deoxy-
cytidine deaminations that result in aberrant processing of the
proviral DNA ends by HIV integrase and inhibition of plus-strand
DNA transfer by reducing the efﬁciency of primer tRNA removal
(Mbisa et al., 2007, 2010).
Deamination-independent HIV restriction by A3F
For many years, A3F was thought to have a stronger deamination-
independent mode of inhibiting HIV than A3G (Bishop et al.,
2006; Holmes et al., 2007). Unlike A3G, the mechanism of
deamination-independent “activity” was not extensively studied,
but was presumed to be due to inhibition of RT polymeriza-
tion. A computational study has found that A3G and A3F rely
differentially on their deamination-independent modes of HIV
restriction with A3G only having the deamination-independent
mode contributing to <1% of its restriction activity whereas for
A3F this value was approximately 30% (Kobayashi et al., 2014).
However, two studies using stably expressed A3F andA3F catalytic
mutants C280S/C283A and E251Q demonstrated no inhibition of
RT, suggesting that previous resultswere inﬂuencedbyA3Foverex-
pression artifacts (Miyagi et al., 2010; Albin et al., 2014). Another
study showed that A3F can inhibit HIV integration by reducing
3′ processing of viral DNA at the U5 and U3 ends by integrase
(Mbisa et al., 2010). Using a catalytic mutant of A3F (E251Q), the
study found that inhibition of integration was decreased approx-
imately twofold from that of WT A3F suggesting that catalytic
activity is in part required to produce the aberrant U5 and U3
ends (Mbisa et al., 2010). Thus there appears to be consensus
that despite the potentially inefﬁcient mutagenic activity of A3F
in some studies, the deamination activity of A3F is still domi-
nant over the deamination-independent activity. Furthermore, if
a deamination-independent mode of HIV inhibition functions in
cells, it may be the inhibition of integration rather than reverse
transcription (Mbisa et al., 2010).
A3D-MEDIATED RESTRICTION OF HIV
A3D was ﬁrst characterized in 2006 to restrict HIV replication in
single-cycle infectivity assays and to be suppressed by Vif, sug-
gesting that it posed a restriction pressure on HIV (Dang et al.,
2006). Further evidence of this was that HIV proviral genomes
showed evidence of deaminations in the contexts of 5′CC, 5′TC,
and 5′GC (Dang et al., 2006). A3D was found to deaminate in
the 5′TC and 5′GC contexts which were unique from A3G and
A3F that maintain less promiscuous deamination motif prefer-
ences (Dang et al., 2006). A3D also forms multimers through
an RNA intermediate in cells with a similar proﬁle as A3G
(Li et al., 2014). In a clinical study of HIV-infected individu-
als, A3D was found to be upregulated in both Elite Controllers
and in Non-Controllers but was down-regulated in response
to successful anti-retroviral treatment, indicating that A3D is
part of a virological immune response to HIV (Abdel-Mohsen
et al., 2013). However, the restrictive activity of A3D appears less
than A3G and A3F in single-cycle infectivity assays in cell lines
(Dang et al., 2006, 2011; Hultquist et al., 2011) and spreading
infections in primary human cells (Chaipan et al., 2013). Fur-
thermore, A3D represents the most divergent A3 enzyme in the
lineage of chimpanzee to humans and the activity of A3D has
decreased from chimpanzees to humans (Duggal et al., 2011).
Other chimpanzee and human A3 enzymes are more commonly
found to have similar restriction potentials (Duggal et al., 2011).
Chimpanzee A3D induces more hypermutation of HIV than
human A3D, despite equivalent packaging into virions (Dug-
gal et al., 2011). This was attributed to differences in loop 7 of
the CTD (Dang et al., 2011; Duggal et al., 2011). One report
found a single amino acid in the CTD loop 7, C320, that sup-
pressed A3D antiviral activity (Dang et al., 2011, Figure 3E).
If the C320 was replaced with a Tyr, as in A3F, the activity
of A3D could be increased by more than 20-fold (Dang et al.,
2011). In contrast, endogenous A3D from the T cell line CEM2n
appears to have activity against HIV-1 that is similar to A3F
(Refsland et al., 2012). Using a series of A3 null backgrounds orA3
knockdowns, Refsland et al. (2012) found that the HIV-1 provi-
ral hypermutation pattern at 5′CC and 5′TC sites was induced
at comparable levels by the combined action of A3G and A3F or
A3G and A3D, suggesting a redundancy in the HIV-1 restriction
mechanism.
A3H-MEDIATED RESTRICTION OF HIV
A3H was originally identiﬁed as not being able to restrict HIV
replication due to low steady-state protein levels in mammalian
cells, despite normalmRNAexpression (Dang et al., 2006; OhAinle
et al., 2006). However, when A3H was recombinantly expressed in
Escherichia coli it could mutate the E. coli genomic DNA (OhAinle
et al., 2006). In later studies, itwas realized thatA3Hexists asmulti-
ple haplotypes in the humanpopulation (Hap I-VII)with different
stabilities in cells and HIV restriction capabilities (Table 1) and the
original A3H tested was an unstable form (Hap I, OhAinle et al.,
2008; Harari et al., 2009). The unstable Hap I is the most prevalent
form of A3H in the population (Table 1), but is able to restrict
HIV infection by approximately twofold when transiently over-
expressed in cell lines (OhAinle et al., 2008; Harari et al., 2009;
Li and Emerman, 2011; Wang et al., 2011a). Two amino acid
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Table 1 | Summary of A3H haplotype features.
A3H
haplotypes
Polymorphic amino acid residues Antiviral activity
in cell culture
Protein
stability
Haplotype
frequency
Reference
15 18 105 121 178
Hap I N R G K E Partial No 0.526a
0.308b
OhAinle et al. (2006), OhAinle et al. (2008),
Dang et al. (2008), OhAinle et al. (2008),
Harari et al. (2009), Ooms et al. (2010,
2013a), Li and Emerman (2011), Wang et al.
(2011b), Zhen et al. (2012)
Hap II N R R D D Yes Yes 0.061a
0.265b
OhAinle et al. (2008), Ooms et al. (2010),
Hultquist et al. (2011), Li and Emerman
(2011), Wang et al. (2011b), Zhen et al.
(2012), Ooms et al. (2013a)
Hap III  R R D D No No 0.070a
0.114b
OhAinle et al. (2008), Wang et al. (2011b),
Ooms et al. (2013a)
Hap IV  L R D D No No 0.088a
0.178b
OhAinle et al. (2008), Harari et al. (2009),
Wang et al. (2011b)
Hap V N R R D E Yes Yes 0.202a
0.054b
OhAinle et al. (2008), Wang et al. (2011b)
Hap VI  L G K D No No 0.026a
0.0004b
OhAinle et al. (2008), Wang et al. (2011b)
Hap VII N R R K E Yes Yes 0.009a
Not detectedb
OhAinle et al. (2008), Wang et al. (2011b)
aWang et al. (2011b).
bOhAinle et al. (2008).
polymorphisms, 105G and 15N, can independently contribute
to the instability of A3H (Table 1). A3H Hap I is unstable due to
a Gly at position 105 (OhAinle et al., 2008). An A3H Hap I G105R
mutant (later identiﬁed as Haplotype VII, Table 1) renders the
A3H stable in cells and imparts strong anti-HIV activity (OhAinle
et al., 2008; Harari et al., 2009). Other unstable A3H haplotypes
(III and IV) have the 15N in combination with another poly-
morphism (OhAinle et al., 2008; Harari et al., 2009, Table 1). It
is not known biochemically why these A3H haplotypes are unsta-
ble, but comparative modeling of A3H with the structure of a
related family member APOBEC2 shows that amino acid 105 is
in a β-strand within the central ﬁve-stranded β-sheet, suggest-
ing that an R105G mutation could destabilize the core structure
(Figure 3F). The  15N is predicted to be within a loop struc-
ture (Figure 3F) so it is difﬁcult to predict the reason for the
instability in this undeﬁned region, but it is known from stud-
ies with A3F that deletions to a loop that connect the NTD and
CTD cause protein instability (Ara et al., 2014), suggesting that the
A3H loop may need to be of a speciﬁc length for proper protein
folding. Although different haplotypes (II, V, and VII) have been
reported to exist in the population as stable forms that are able
to restrict HIV (Table 1), in this review we focus only on A3H
Hap II (A3H Hap II), which has been the most highly studied.
Notably, A3H Hap II has some variability in its restriction ability
which is dependent on alternative mRNA spliced forms (Harari
et al., 2009). A3H Hap II is primarily found in Africans/African
Americans (∼50%) and to a much lesser extent within other cul-
tural populations (prevalence of approximately 0–8%, OhAinle
et al., 2008; Wang et al., 2011b). It has been proposed that A3H
evolved to become unstable due to a combination of the loss of
an ancient pathogen and the ability of an ancestral A3H to induce
mutagenesis of genomic DNA (Jern and Cofﬁn, 2008; OhAinle
et al., 2008).
A3H is the only A3 enzyme with highly diversiﬁed antiviral
activities based on sequence polymorphisms (Li and Emerman,
2011; Duggal et al., 2013) and appears to be in a category of
its own in relation to other A3 enzymes regarding two other
aspects. First, A3D, A3F, and A3G that also restrict HIV repli-
cation have two Z-type domains, whereas A3H has only one
Z-domain (LaRue et al., 2008, Figure 1). Phylogenic analyses
have shown that the A3 Z-type domains have three distinct cat-
egories (Z1, Z2, and Z3) and A3H is the only A3 enzyme with
an Z3 (LaRue et al., 2008, Figure 1). A3D and A3F have two
Z2 domains and A3G has an Z1 (CTD) and Z2 (NTD) domain
(LaRue et al., 2008, Figure 1). Second, A3H is the only single Z-
type domain A3 (others are A3A and A3C) that forms oligomers
and multimers. Structural and biochemical studies have found
that A3A and A3C are largely monomeric (>90%) in solution and
do not multimerize in cells through an RNA intermediate (Kita-
mura et al., 2012; Love et al., 2012; Byeon et al., 2013; Li et al.,
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2014; Logue et al., 2014; Shlyakhtenko et al., 2014). In contrast,
A3H Hap II was found to multimerize in cells (Li et al., 2014).
The A3H Hap II multimerization in cells was shown by ﬂuo-
rescence ﬂuctuation spectroscopy and determined that multiple
A3H Hap II molecules could closely associate on RNA, not that
A3H Hap II oligomerized through a protein–protein interaction
(Li et al., 2014). It remains to be determined if A3H Hap II can
form a dimer in solution in the absence of RNA or DNA. A3G
and A3F form oligomers in the absence of nucleic acid suggest-
ing that A3 oligomerization ability facilitates the multimerization
of A3 enzymes with RNA in cells (Chelico et al., 2008; Shlyakht-
enko et al., 2011; Ara et al., 2014). It has been shown that similar
to A3G and A3F, A3H Hap II interacts with cellular RNA and
the NC portion of Gag to facilitate its encapsidation into HIV
particles (Wang et al., 2011a; Zhen et al., 2012). Studies on A3H
Hap II and Hap I have also shown that cytoplasmic localiza-
tion correlates with restriction efﬁciency since mutation of A3H
Hap I to make it cytoplasmic (G105R) increases its restriction
capacity despite other amino acid differences from A3H Hap
II (Harari et al., 2009; Li et al., 2010). Additionally, virion mis-
localization of certain A3H haplotypes may render them less
active against HIV (Ooms et al., 2010). For example, despite
nuclear localization of A3H Hap I, it can be encapsidated into
HIV particles, but through an association with the matrix and
capsid region of Gag, which leads to its primary localization
outside the capsid (Ooms et al., 2010). These data suggest that
both cellular and virion localization play a role in restriction
efﬁciency. There has been limited information in the literature
on the biochemical properties of A3H and how different haplo-
types bind and scan ssDNA in search for deamination targets.
A3H Hap II prefers to deaminate ssDNA at 5′TC sites, similar
to A3F and A3D, and appears have a high mutagenic potential
and ability to restrict HIV in both single-cycle and spreading
infection experiments and in HIV-infected individuals (Harari
et al., 2009; Hultquist et al., 2011; Wang et al., 2011a; Ooms et al.,
2013a).
RESTRICTION OF HIV BY COORDINATELY EXPRESSED A3 ENZYMES
Vif-deﬁcient HIV showed replication defects when produced from
cell lines such as CEM and H9, resulting in their classiﬁcation as
non-permissive cell lines (Gabuzda et al., 1992; Blanc et al., 1993;
Sakai et al., 1993; von Schwedler et al., 1993; Madani and Kabat,
1998; Simon et al., 1998). After many years of investigating the
function of Vif and trying to understand the dichotomous phe-
nomenon of permissive and non-permissive cell lines for Vif
HIV, Sheehy et al. (2002) found that the non-permissive CEM cell
line expressed A3G. Thereafter, many groups discovered that Vif
was required to induce degradation of A3G to enable HIV repli-
cation (Sheehy et al., 2002, 2003; Conticello et al., 2003; Kao et al.,
2003; Mariani et al., 2003; Marin et al., 2003; Stopak et al., 2003; Yu
et al., 2003). Later, it was realized by analyzing the mRNA expres-
sion levels of A3s using quantitative PCR in permissive (CEM-SS,
SupT1) and non-permissive (CEM and H9) T cell lines that the
classical non-permissive CEM T cell line expressed not only A3G
but also A3F and A3D, albeit with lower mRNA levels (Refs-
land et al., 2010). It is interesting to speculate whether more data
would be available on the inhibition of HIV by the combined
action of multiple A3s if they were discovered at the same time
as A3G.
In primary CD4+ T cells A3 enzymes relevant to HIV restric-
tion are expressed and further induced by mitogens, rather than
interferon, indicative of their function in restricting retrotrans-
posons (Koning et al., 2009; Refsland et al., 2010). In contrast,
in macrophages, monocytes and dendritic cells expression of
select A3 enzymes is induced by interferon (Koning et al., 2009;
Refsland et al., 2010). Although A3 enzymes are not individually
expressed in cells as in many laboratory experiments (Refsland
et al., 2010, 2012), there is an advantage of individual expression
of each A3. Individual expression of A3 enzymes enables mech-
anistic information to be learned about enzyme function and
mutational footprints established. However, A3s with perhaps a
lesser restriction efﬁciency would not be expressed alone during
an HIV infection suggesting that it may not matter per se which
enzyme is most effective since they may each contribute coopera-
tively to HIV restriction. Gillick et al. (2013) found that in primary
human CD4+ T cells the majority of proviral mutations were
in a sequence context that indicated A3G-induced mutations are
dominant (5′CC), but A3F- and A3D-induced mutations (5′TC
context) were evident at ninefold less frequency than the 5′CC
context in Vif HIV. This is in contrast to a study by Ooms et al.
(2013a) that used peripheral blood mononuclear cells to exam-
ine the hypermutation of HIV in the absence or presence of A3H
Hap II. In the absence of A3H Hap II, it was found using a deep
sequencing approach that there was approximately an equal num-
ber of mutations originating in 5′CCand5′TCcontexts, suggesting
that A3F and A3D cooperate to induce an equivalent number of
mutations to A3G (Ooms et al., 2013a), in agreement with results
from a CEM2n T cell line (Refsland et al., 2012). In the presence
of Vif that could induce degradation of all A3s except A3H Hap II,
there was a large number of mutations in the 5′TC context demon-
strating that A3H when present in a stable form is highly active
against HIV (Ooms et al., 2013a).
Although the use of spreading infections in primary cells or
T cell lines supports the idea that A3s cooperate, there still may
be a question of whether they induce HIV evolution. It has been
proposed that if there is an insufﬁcient amount of A3-induced
hypermutation this may beneﬁt HIV and contribute to sequence
variation by induction of sublethal levels of mutagenesis which
results in HIV evolution (Mulder et al., 2008; Kim et al., 2010;
Sadler et al., 2010; Monajemi et al., 2014). There is evidence that
A3G andA3F hotspots are enriched in immunogenic CTL epitopes
and thatHIVmay utilizeA3s to induce immune escape (Monajemi
et al., 2014). In addition, A3G may be able to induce resistance
to the RT inhibitor lamivudine (3TC) because its deamination
motif overlaps with a codon for Met and results in an M146I
mutation in the pol gene (Mulder et al., 2008; Kim et al., 2010).
However, the frequency of this mutation being induced by A3G
versus RT activity has been questioned (Jern et al., 2009). It is also
not known if A3F/A3D/A3HHap II induce this evolution anymore
thanA3G,due to differences in inactivation potential derived from
their sequence speciﬁcities (Yu et al., 2004; Zennou and Bieniasz,
2006; Love et al., 2012; Ara et al., 2014) and if this impacts disease
progression in infected individuals. On the other hand, Vif has
been shown to adapt within HIV-infected individuals and be less
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effective in inducing A3 degradation (Simon et al., 2005; Fourati
et al., 2010). It is thought that HIV can utilize Vif as a mutational
rheostat in times of viral stress by allowing lowamounts of A3s into
viral particles to induce sublethal mutagenesis (Simon et al., 2005;
Fourati et al., 2010). These types of studies have raised the idea
that perhaps inducing hypomutation or shutting off A3 enzymes
may beneﬁt HIV-infected individuals (Harris, 2008; Hultquist and
Harris, 2009).
HIV Vif
GENERAL PROPERTIES
The main function of Vif remained elusive at the beginning of
HIV research, except for the ﬁnding that Vif made some cell
lines permissive for producing HIV particles capable of under-
going another round of infection (Fisher et al., 1987; Strebel et al.,
1987). Non-permissive cells allowed a Vif HIV to produce virus
particles, but they were rendered non-infectious upon infection of
fresh cells. Two laboratories discovered that Vif repressed a host
factor (Madani and Kabat, 1998; Simon et al., 1998). It was later
identiﬁed by subtractive hybridization that A3G (originally called
CEM15) was the host factor that was highly packaged into virions
in the absence of Vif and blocked infection in the next target cell
(Sheehy et al., 2002, Figure 2A). Although this is clearly a primary
role for HIV infectivity,Vif was also shown to inﬂuence HIV parti-
cle morphology and this may relate to its potential role as a nucleic
acid chaperone (von Schwedler et al., 1993; Hoglund et al., 1994;
Henriet et al., 2007; Batisse et al., 2012).
Vif AS AN E3 UBIQUITIN LIGASE SUBSTRATE RECEPTOR
In 2012 it was discovered thatVif interacts with the host transcrip-
tion cofactor CBFβ for stability in cells (Jager et al., 2012; Zhang
et al., 2012). The interaction is mediated through Vif amino acids
84GxSIEW89 and 102LADQLI107 (Matsui et al., 2014b; Wang et al.,
2014, Figures 5A,B). TheVif/CBFβ complex is also required for in
vitro stability of Vif and enables recombinant expression of Vif in a
largely soluble form in E. coli that can be puriﬁed for biochemical
studies (Zhou et al., 2012). In contrast, Vif alone expressed in E.
coli accumulates in inclusion bodies and must be puriﬁed under
denaturing conditions (Yang et al., 1996). To suppressA3 actionVif
interacts directly with A3 enzymes and mimics the human protein
suppressor of cytokine signaling-2 (SOCS2) to become the sub-
strate recognition subunit of a Cullin RING ligase-5 (CRL5) E3
ligase complex (Figure 2B).
Vif interacts with host proteins Elongin C, which forms an
obligate heterodimer with Elongin B (EloB/C) and Cullin 5 (Cul5,
Marin et al., 2003;Yu et al., 2003,2004;Mehle et al., 2004; Luo et al.,
2005; Xiao et al., 2007; Stanley et al., 2008; Bergeron et al., 2010).
The interaction of Vif with EloB/C increases the stability of Vif in
cells and in vitro and promotes recruitment of CBFβ (Wang et al.,
2013). The interaction of Vif with EloC is mediated through an
SLQ motif inVif termed the Elongin B/C (BC) box (Yu et al., 2003,
2004, Figures 5A,B, 144SLQYLA149), similar to human SOCS pro-
teins (Kamura et al., 1998; Iwai et al., 1999). Distinct from human
proteins is that Vif does not have the highly conserved Cys in
the BC box and instead has a 149A (Kamura et al., 1998, 2004,
Figures 5A,B). The data with Vif suggest that it is the short side
chain of the amino acid at position 149 rather than the Cys that is
required for the interactionwith EloC (Yu et al., 2004; Stanley et al.,
2008). Vif also does not contain a canonical Cul5 box (Luo et al.,
2005; Xiao et al., 2007). In search of the conserved Cys in the BC
box, two other Cys (114C, 133C) were identiﬁed in Vif upstream
of the BC box and were found to be involved in binding with
Cul5 (Mehle et al., 2004; Yu et al., 2004). These Cys were found
to be part of a novel Zinc binding HCCH motif (Figures 5A,B,
108Hx2YFxCFx4IRx2LxGx6CxYx3H139). The Zinc coordination in
the HCCH was predicted to stabilize a small domain of Vif and
indirectly support Cul5 binding (Luo et al., 2005). The primaryVif
amino acids that contactCul5 are at positions 120–121 and 124 in a
helix that is adjacent to the HCCH residues (Xiao et al., 2006; Guo
et al., 2014,Figures 5A,B, 120IRxxL124). TheVif/CBFβ/EloB/Chet-
erotetramer undergoes a conformational change that promotes
binding to Cul5, suggesting that there is a prescribed order in
the assembly of the E3 CRL5 ligase complex (Fribourgh et al.,
2014). Accordingly, Cul5 binds less well to EloB/C in the absence
of Vif/CBFβ (Guo et al., 2014).
A recent structural study of Vif bound to CBFβ/EloB/C/Cul5
shows that Vif has an overall elongated cone structure and con-
tains two domains with a Zinc binding domain in the center of
the two domains (Guo et al., 2014, Figure 5C). CBFβ binds the
N-terminal α/β-domain and EloC and Cul5 bind the C-terminal
α-domain of Vif (Guo et al., 2014, Figure 5C). Both EloC and
Cul5 interact with Vif through hydrophobic interfaces on distinct
α-helices (Xiao et al., 2006; Guo et al., 2014). The crystal struc-
ture also emphasizes the stability that CBFβ imparts to Vif since
they have a total interaction surface area of 4797 Å2 and form an
antiparallel β-sheet with a β-strand from each protein (Guo et al.,
2014). The side of CBFβ that is bound by Vif is the same side that
the humanCBFβ binding partner, the RUNX1 transcription factor
binds to suggesting a mutually exclusive binding (Kim et al., 2013;
Guo et al., 2014), although other reports show CBFβ can bind Vif
and RUNX1 on genetically distinct surfaces (Hultquist et al., 2012;
Zhang et al., 2012; Du et al., 2013a). Functionally, Vif appears to
exclude CBFβ from binding RUNX1 because expression of Vif can
alter the RUNX1-dependent transcriptional proﬁle of cells and
suggests that Vif may have multimodal effects in HIV-infected
cells (Kim et al., 2013).
CBFβ interacts with a hydrophobic region of the Vif α/β-
domain, but the rest of the exposed α/β-domain surface is highly
positively charged and is thought to mediate electrostatic inter-
actions with A3 enzymes (Aydin et al., 2014; Guo et al., 2014).
To target A3s for proteasomal degradation, Cul5 interacts with
RING ﬁnger protein 2 (Rbx2, Jager et al., 2012) and this results
in the assembly of a hexameric complex (Figure 2B). Further-
more, an E2 ubiquitin conjugating enzyme interacts with the
hexamer through Rbx2 and causes 48K-linked polyubiquitina-
tion of the A3 enzyme, on multiple lysine residues signaling it
for degradation through the proteasome pathway (Figure 2B).
Current data for A3G and A3F suggest that the Lys residues
that become conjugated to ubiquitin are random (Albin et al.,
2013).
Vif amino acids that interact with A3s
Alanine scanning mutagenesis of Vif or comparison of different
Vif variants from HIV subtypes has enabled the identiﬁcation of
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FIGURE 5 | Structure of Vif and host interacting partners. (A) Domain
organization of Vif. Vif uses speciﬁc motifs to interact with A3G (magenta,
40YRHHY44), A3F/A3C/A3D (red, 11WQxDRMR17 and 74TGERxW79), and
A3H (orange, 39F and 48H). In conjunction with these speciﬁc motifs, there
are shared interaction motifs for A3F and A3G with Vif (pink, 21WKSLVK26
and 69YWxL72). CBFβ interacts with Vif through two adjacent motifs (cyan,
84GxSIEW89 and 102LADQLI107). The Zinc ﬁnger region (green, amino acids
108-139) coordinates the Zinc through an 108H114C133C139H motif and
stabilizes the Vif structure, which indirectly enables an interaction with
Cullin 5 (Cul5). Direct interaction of Vif with Cul5 is through amino acids
120IRxxL124. The BC box mediates an interaction with Elongin C (green
144SLQYLA149). Vif oligomerizes through a PPLP motif (gray,
163PPLPx4L169). Slanted lines are used to indicate intervening amino acids
between the domains. (B) The crystal structure of Vif (PDB: 4N9F) shows
that it has two domains on either side of a bound Zinc (blue). The
N-terminal α/β-domain consists of a ﬁve stranded β-sheet, a discontinuous
β-strand and three α-helices. The α/β-domain contains the binding interface
for CBFβ (cyan, 102LADQLI107, 84GxSIEW89) and A3 enzymes. The
11WQxDRMR17 motif (red) is used to interact with A3F, A3C, and A3D, the
40YRHHY44 motif (magenta) is used to interact with A3G, and residues 39F
and 48H (orange) are used to interact with A3H. The α-domain contains two
alpha helices that mediate two separate interactions with EloC (green,
144SLQYLA149) and Cul5 (green, 120IRxxL124). (C) Structure HIV Vif (red) in
complex with CBFβ (cyan), Elongin C (EloC, yellow), and the N-terminal
domain of Cullin 5 (nCul5, amino acids 12–386, orange, PDB: 4N9F).
Elongin B (EloB, magenta) dimerizes with EloC. Figures were made using
PyMOL (The PyMOL Molecular Graphics System, Version 1.5.05,
Shrödinger, LLC.).
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three distinct regions of Vif that interact withA3G,A3F/A3D/A3C,
or A3H (Huthoff and Malim, 2007; Russell et al., 2009b; Binka
et al., 2012, Figure 5A). Vif interacts with A3G through two
positively charged regions on Vif, 21WxSLVK26 and 40YRHHY44
(Mehle et al., 2007; Russell and Pathak, 2007; Yamashita et al.,
2008; Chen et al., 2009; Dang et al., 2009, Figures 5A,B). Sim-
ilarly, various domains in Vif have been identiﬁed to interact
with A3F, speciﬁcally 11WQxDRMR17 and 74TGERxW79 (Tian
et al., 2006; Russell and Pathak, 2007; He et al., 2008; Yamashita
et al., 2008, Figures 5A,B). In addition, the 69YWxL72 motif is a
region of Vif that interacts with both A3G and A3F (He et al.,
2008; Pery et al., 2009, Figure 5A). However, for both A3G
and A3F mutation of the 40YRHHY44 and 14DRMR17 motifs
to all alanines are necessary and sufﬁcient to block Vif-induced
A3G and A3F degradation, respectively, suggesting the other
domains provide a secondary stabilizing interaction (Russell and
Pathak, 2007). Of note, A3C and A3D share a common binding
site on Vif as A3F with 14DRMR17 shown to be of importance
(Pery et al., 2009; Kitamura et al., 2011, 2012, Figures 5A,B). Vif
interacts with A3H through another unique site that involves
amino acid 39F and 48H (Binka et al., 2012; Ooms et al., 2013b,
Figures 5A,B).
The Vif amino acids that interact with A3H are not highly
conserved among HIV subtypes, in contrast to the motifs of Vif
that interact with A3G and A3F/A3D. It has been suggested that
since HIV rarely encounters a host with an active A3H allele,
there has been evolutionary drift of Vif to not maintain an inter-
action site with A3H (Ooms et al., 2013a). As a result, A3H is
differentially sensitive to Vif variants. For example, A3H Hap
II is not sensitive to HIV NL4-3 Vif (39F, 48N), but is sensitive
to HIV LAI Vif (39F, 48H, Ooms et al., 2013b). The inability of
some Vif variants to induce degradation of A3H Hap II enabled
Ooms et al. (2013a) to test whether A3H could act as an infec-
tion barrier to HIV. Ooms et al. (2013a) found that Vif will adapt
in infected individuals to induce degradation of A3H Hap II (Li
et al., 2010). Importantly, this evolution of Vif affects only A3H
and Vif maintains the ability to induce degradation of A3G and
A3F (Ooms et al., 2013a), conﬁrming that Vif indeed uses three
distinct interfaces to interact with A3 enzymes and supports the
idea that multiple A3 enzymes coordinately exert a restriction
pressure on HIV. Importantly, treatment naïve HIV-infected indi-
viduals at the early or primary infection stage that had at least
one active A3H allele (Hap II) had higher levels of mutations
in proviral genomes in a 5′TC context, lower viral loads and
higher CD4+ T cell counts (Ooms et al., 2013a). Gourraud et al.
(2011) similarly reported that early stage, untreated HIV-infected
individuals that were homozygous for a stable A3H allele demon-
strated lower HIV RNA over time, but this did not correlate with
increased hypermutation of HIV proviral genomes. This differ-
ence in mutational load between these reports is likely due to
the different sequencing strategies used between the two stud-
ies (Gourraud et al., 2011; Ooms et al., 2013a). These data are
similar to clinical data obtained with A3G and A3F that demon-
strate in a number of cohorts (but not all), A3G or A3F mRNA
expression or hypermutation levels correlate with high CD4+
T cell counts and low viremia (reviewed in Albin and Harris,
2010).
Vif–A3G interaction
The Vif–A3G interaction was the ﬁrst Vif–A3 interaction to be
studied and it established that Vif inhibits the antiviral activity
of A3 enzymes in a species-speciﬁc manner (Bogerd et al., 2004;
Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al., 2004;
Etienne et al., 2013; Letko et al., 2013). This means that HIV Vif
cannot neutralize A3G from African green monkey (AGM), and
AGM SIV Vif cannot neutralize A3G from humans and this has
been recognized as a cross-species infection barrier (Bogerd et al.,
2004; Mangeat et al., 2004; Schrofelbauer et al., 2004; Xu et al.,
2004; Etienne et al., 2013; Letko et al., 2013). Initially, to identify
the residues HIV Vif uses to interact with human A3G the human
A3G amino acids were replaced with those of AGM or rhesus
macaque A3G. Mutation of human A3G 128D to 128K as found
in AGM and rhesus macaque A3G abrogated the interaction of
HIV Vif with human A3G and its ability to induce degradation of
human A3G (Bogerd et al., 2004; Mangeat et al., 2004; Schrofel-
bauer et al., 2004). However, when the 128D was mutated to 128A,
HIVVif could still interact with and degrade human A3G demon-
strating that the charged interface was more important than the
amino acid identity (Schrofelbauer et al., 2004). Since mutation of
solely 128D to 128K can abrogate the interaction between A3G and
Vif in co-immunoprecipitation studies it is clearly a determining
residue. However, Vif-mediated degradation can be inﬂuenced
by mutation of A3G 129P and 130D and Vif also interacts with
A3G on surrounding motifs such as helix 6 (Huthoff and Malim,
2007; Lavens et al., 2010; Feng et al., 2013, Figure 3A). The loop
7 and helix 6 regions contain more positively charged and neu-
tral amino acids than negatively charged amino acids which may
explain why 128D is such an important contact point for the pos-
itively charged Vif, despite a larger A3G interface predicted from
biochemical studies. These studies with A3G established the prin-
ciple that a lack of Vif-induced degradation correlates with a lack
of an interaction between the A3 and Vif.
Vif–A3F/A3D interaction
A3F and A3D share the same structural motif in the CTD that
interacts with Vif (Smith and Pathak, 2010; Kitamura et al., 2012,
Figures 3D,E). A3F has been studied more extensively than A3D
in this regard and will be discussed here. In contrast to A3G, there
was no speciﬁc single amino acid determinant identiﬁed for A3F
that clearly mediated both the primary interaction with Vif and
was a determinant for Vif-mediated degradation. Rather, differ-
ent groups identiﬁed different amino acids in A3F that altered its
susceptibility to Vif. Smith and Pathak (2010) reported that A3F
interacts with Vif through CTD amino acids 289EFLARH294 and
that 289E was critical for A3F sensitivity to Vif. Albin et al. (2010b)
identiﬁed another residue, 324E, as the key determinant of A3F to
Vif-mediated degradation, but mutation of 324E to other amino
acids, even those of opposite charge, didnot disrupt the interaction
between A3F and Vif under stringent co-immunoprecipitation
conditions. Although other groups have found that the interaction
of A3F and Vif could be disrupted at least partially by mutating
324E, therewas awider regionof A3F that appeared to be important
for Vif-mediated degradation in comparison to what was identi-
ﬁed for A3G (Albin et al., 2010b; Kitamura et al., 2012; Siu et al.,
2013). A combination of mutagenesis, structural modeling and a
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crystal structure of A3C, that shares the sameVif binding interface
withA3F andA3D, identiﬁed a novel type of A3 andVif interaction
(Smith and Pathak, 2010; Kitamura et al., 2012). Rather than Vif
interacting with a loop as in the case of A3G (Figure 3A, loop 7),
Vif interacted with a negatively charged surface of A3F/A3D/A3C
that spanned helix 2, 3, and 4 and β-strand 4 (Kitamura et al., 2012;
Aydin et al., 2014, Figures 3D,E). This negatively charged surface
supports the hypothesis that it is primarily electrostatic interac-
tions that mediated the A3 and Vif interaction and provides an
explanation for why the A3F and Vif interaction may be more dif-
ﬁcult to disrupt than the primarily neutral surface present in A3G.
It is not known if this would mediate a tighter interaction of Vif
withA3F thanA3Gsince there are noquantitative data available for
both A3G and A3F using the same experimental conditions (Feng
et al., 2013; Siu et al., 2013). Studies with A3F have shown that
a lack of Vif-induced degradation does not necessarily correlate
with a lack of a Vif-A3F interaction, suggesting that the binding
orientation or other factors contribute to successful Vif-mediated
degradation rather than only the presence of an interaction (Albin
et al., 2010b).
Vif–A3H interaction
A3Hsensitivity toVif is haplotype dependent (OhAinle et al., 2008;
Harari et al., 2009; Tan et al., 2009; Li et al., 2010; Hultquist et al.,
2011; Binka et al., 2012). TheA3HHap I is not sensitive toHIVLAI
Vif-mediated degradation whereas A3H Hap II is sensitive to HIV
LAI Vif-mediated degradation (Harari et al., 2009; Li et al., 2010;
Zhen et al., 2010; Ooms et al., 2013b). The A3H haplotype poly-
morphisms only occur at three locations (amino acids 105, 121,
and 178,Table 1). A3H Hap I encodes GKE at these three positions
andA3HHap II encodes RDDat these positions. It was shown that
at position 105, theArg is required for stable expression in cells and
that the 178 position had little effect on Vif-mediated degradation
(OhAinle et al., 2008; Harari et al., 2009; Li et al., 2010). Therefore,
a single amino acid homologous to A3G 128D at position 121 in
A3H Hap II was determined to control sensitivity to Vif-mediated
degradation (Li et al., 2010; Zhen et al., 2010, Figure 3F). An A3H
Hap II mutant with a 121K is not sensitive to Vif-mediated degra-
dation and does not interact withVif (Zhen et al., 2010). From the
A3H structural model (Figure 3F), it appears that the 121D of A3H
is not located on loop 7 as in A3G, but is on helix 4 and on a dif-
ferent face of the molecule (compare Figures 3A,F). Yet, similar to
A3G the region surrounding 121D is mainly neutral or positively
charged residues, in contrast to the negatively charged interface
that Vif uses to interact with A3F and A3D (Aydin et al., 2014).
DEGRADATION INDEPENDENT INHIBITION OF A3G
Although Vif primarily inhibits A3G by inducing its proteaso-
mal degradation, there have been other ways in which Vif can
inhibit A3G encapsidation or function through a degradation-
independent route. Vif may not be able to completely degrade
the A3G in the virus-producing cell and these degradation-
independent mechanisms may be another line of defense against
A3G virion encapsidation. In particular, Vif can become the tar-
get of A3-mediated hypermutation (Simon et al., 2005; Jern et al.,
2009), which may result in a Vif unable to interact with the E3
CRL5 ligase complex, but still able to inhibit A3G through a
degradation-independent mechanism. It is not known if Vif can
act in this manner for other A3 enzymes.
Vif decreases translation of A3G mRNA
Vif can decrease A3G mRNA translation in order to lower the
steady-state levels of A3G through a Vif and A3G mRNA interac-
tion, but the exact mechanism is not understood (Kao et al., 2003;
Stopak et al., 2003; Mercenne et al., 2010). It is known that Vif can
decrease the mRNA levels of A3G by 15–40% and this requires
that Vif interact with the 5′UTR of the A3G mRNA (Stopak et al.,
2003; Mercenne et al., 2010). Since Vif has been shown in an
immunoﬂuorescence study to co-localize with A3 enzymes and
P-bodies (Marin et al., 2008), it is possible that Vif shuttles A3G
mRNA to P-bodies to delay or prevent mRNA translation.
Vif inhibits virion encapsidation of A3G
Studies by Goila-Gaur et al. (2008) have shown that A3G synthe-
sized in vitro using a rabbit reticulocyte lysate translation system
would become immunoprecipitation and packaging incompetent
in the presence of Vif. Vif was not associated with these high
molecular mass A3G forms, but was required for their forma-
tion (Goila-Gaur et al., 2008). Although A3G regularly forms high
molecular mass complexes in cells, which are less likely to be pack-
aged into virions, Vif can induce an even higher molecular weight
formof A3G (Soros et al., 2007; Goila-Gaur et al., 2008). Moreover,
studies with anA3G C97A mutant that is resistant toVif-mediated
degradation suggested that Vif-mediated degradation and inhibi-
tion of packaging are two distinct properties of A3G since the A3G
C97A mutant was encapsidated less well in the presence of Vif
(Opi et al., 2007). A molecular mechanism for this effect has not
been described.
Vif inhibits deamination of deoxycytidine by virion-encapsidated
A3G
A3 enzymes are mainly studied with HIVvif in order to observe
restriction in single-cycle infectivity assays, but in infected indi-
viduals A3 enzymes must contend with Vif. Despite multiple
mechanisms that Vif uses to block A3G, it has been shown that
A3G is encapsidated in the presence of Vif, albeit in lesser amounts
(Nowarski et al., 2008). However, per molecule of A3G there is less
deamination activity (Britan-Rosich et al., 2011, Figure 2E). This
decrease in A3G deamination activity even occurs when A3G and
Vif are coexpressed in E. coli and mutations are detected with a
Rifampicin reversion assay or in vitro with puriﬁed A3G and Vif,
demonstrating that other viral components arenot required for the
inhibition to take place (Santa-Marta et al., 2005; Britan-Rosich
et al., 2011; Feng et al., 2013). Enzymatic studies have shown that
Vif can cause a decrease in the speciﬁc activity of A3G and that
this is due to a combination of Vif competitively binding to the
ssDNA substrate and Vif binding directly to A3G (Britan-Rosich
et al., 2011; Feng et al., 2013). These are separable functions of Vif
since ssDNA-binding studies of the Vif–A3G complex in compar-
ison to each of the components binding ssDNA alone support the
hypothesis that Vif bound to A3G is unable to bind ssDNA with
high afﬁnity (Feng et al., 2013). Another consequence of Vif bind-
ing to A3G is that it disrupts how A3G scans ssDNA in search of
cytosines to deaminate (Feng et al., 2013). Vif interacts with the
A3G NTD on loop 7, which is required for processive jumping
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movements (Feng and Chelico, 2011, Figure 3A). In a study that
used two Vif variants to examine the effect of Vif/CBFβ on the
deamination activity of A3G it was found that HIV HXB2 Vif
inhibited A3G jumping movements, consistent with an interac-
tion of Vif on loop 7 (Feng et al., 2013). In contrast, HIV NL4-3
Vif inhibited A3G sliding, which is mediated by helix 6, providing
functional evidence that beyond the key loop 7 contact residues,
128DPD130, Vif variants can interact with different regions of A3G
(Feng et al., 2013). This appears to have no functional consequence
for A3G-mediated degradation (Binka et al., 2012), but provides
insights on how variable the Vif variants can be in their extended
binding sites on A3 enzymes. This may affect strategies that aim to
use small molecule inhibitors of the Vif-A3 interaction as an HIV
therapy. Importantly, it has been shown that the speciﬁc activ-
ity of an A3 enzyme is not of primary importance for high levels
of deoxycytidine deamination during reverse transcription (Feng
et al., 2013; Ara et al., 2014). Rather, the method of efﬁciently
searching for the cytosines, i.e., the enzyme’s processive mecha-
nism appears to be of more importance (Feng et al., 2013; Ara
et al., 2014). All together the data suggest that the mechanism by
which Vif inhibits A3G deamination activity in virions is by alter-
ing the searching mechanism used to ﬁnd cytosines on ssDNA.
Inhibition of A3G deaminase activity by Vif is likely to result in
sublethal mutagenesis of HIV and could contribute to the gener-
ation of viral quasispecies and HIV evolution (Sadler et al., 2010;
Feng et al., 2013).
DEVELOPMENT OF SMALL-MOLECULE INHIBITORS FOR
A3-BASED HIV THERAPEUTICS
The A3-HIV host and pathogen relationship creates the possibil-
ity of developing novel therapeutics (Greene et al., 2008; Albin
and Harris, 2010) and high-throughput screening approaches for
small-molecule inhibitors have uncovered positive results. There
are strategies to induce either A3G-mediated viral hypermutation
by disrupting the Vif-A3G interaction (Nathans et al., 2008; Cen
et al., 2010; Nowotny et al., 2010; Ejima et al., 2011; Ali et al., 2012;
Mohammed et al., 2012; Matsui et al., 2014a) or viral hypomuta-
tion by blocking A3G catalytic activity (Li et al., 2012; Olson et al.,
2013). For the “therapy by hypermutation” strategy, the rationale
is to ﬁnd small-molecule inhibitors that antagonize Vif function
and increase the cellular level of A3G available for virus restriction.
A few candidate molecules that recover A3G expression levels and
enable HIV restriction in the presence of Vif have been discovered
(Nathans et al., 2008; Cen et al., 2010; Nowotny et al., 2010; Ejima
et al., 2011; Ali et al., 2012; Mohammed et al., 2012; Matsui et al.,
2014a), although there are little biochemical data to understand
themechanismof action. For the“therapy byhypomutation”strat-
egy, small-molecule inhibitors have been designed that target a key
residue in A3G (C321) that inhibits the catalytic activity of A3G
(Li et al., 2012; Olson et al., 2013). It is thought that decreasing the
viral quasispecies that may arise due to A3-mediated mutagenesis
can assist in immune clearance of the virus and decrease resistance
to antivirals (Harris, 2008; Hultquist and Harris, 2009).
Inhibitors targeted to Vif may only be successful if adminis-
tered in a cocktail to cycle their use and prevent the development
of drug resistance, a long-standing therapy regimen for HIV-1
drugs (Greene, 2007). One strategy to avoid selection of resistant
Vif variants is to utilize the anti-HIV potential of each A3 enzyme
and design inhibitors that bind different regions of Vif, based on
the unique interactions that Vif has with A3G, A3F/D, and A3H
(Figure 5A). However, more study is required to determine if all
A3 enzymes function equally well as individual restriction factors
otherwise, the strategy may need to involve inhibiting degradation
of all A3 enzymes together to enable a strong restriction pressure
onHIV.Development of inhibitors that target theA3 enzymesmay
be a problematic route when considering A3G since Vif interacts
with A3G near the amino acid residues needed for virion incor-
poration, oligomerization, and processivity (Huthoff and Malim,
2007; Huthoff et al., 2009; Feng et al., 2013, Figure 3A). As a result,
the inhibitor molecule may decrease A3G anti-HIV activity. It is
unknown whether the activity of A3D, A3H, or A3F would be
affected by this type of strategy. Furthermore, it has been shown
in the case of A3G, that HIV can overcome the restriction pressure
of A3G by acquiring mutations in genetic sequences other thanVif
in order to indirectly avoid A3G encapsidation (Hache et al., 2008,
2009).
If Vif were unable to interact withCRL5E3 ligase complex com-
ponents, the accelerated degradation of A3G would be blocked.
This strategy has been raised as a potential option (Greene et al.,
2008; Bergeron et al., 2010; Zuo et al., 2012) and current struc-
tural data on the EloB/C-, Cul5-, and CBFβ- Vif interfaces could
facilitate development of inhibitors (Stanley et al., 2008; Guo
et al., 2014). However, the consequence of targeting the host pro-
teins with small molecules remains unknown. In addition, this
approach has potential drawbacks since Vif may remain bound to
theA3 enzymes. ForA3G, this has been shown to lead to a decrease
in mutagenic activity (Britan-Rosich et al., 2011; Feng et al., 2013).
There are no published studies investigating whether Vif would
affect the mutagenic activity of other A3s. If Vif were unable to
interact with CBFβ it would become unstable in the host cells and
degradation of A3 enzymes would be circumvented (Jager et al.,
2012; Zhang et al., 2012). However, targeting a small molecule to
CBFβmay be problematic if this prevents CBFβ from functioning
as the transcription cofactor for RUNX proteins. Although some
reports show that Vif and RUNX1 interact with CBFβ on distinct
surfaces (Hultquist et al., 2012; Zhang et al., 2012; Du et al., 2013b),
Kim et al. (2013) demonstrated thatVif recruitment of CBFβ alters
the transcriptional proﬁle of the cell by preventing RUNX1 and
CBFβ association.
PERSPECTIVES
A3 enzymes have the potential to be manipulated as a therapeutic
mechanism to suppress HIV replication. Over the past decade, an
immense amount of information has been learned regarding each
individual A3 enzyme. Cellular, biochemical, and structural data
have provided insights on how A3 enzymes interact with nucleic
acids andVif and these data can be strategically applied to develop
novel therapies. Critical to predicting the success of an A3-based
strategy requires long-term culture of the virus with the potential
small molecules to identify tactics HIV could use to overcome
the suppression. Another critical facet is understanding if it is
necessary for A3 enzymes to work together to restrict HIV in vivo
in order to invoke the most restrictive pressure on the virus and
prevent sublethal mutagenesis.
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